drago - If you bought shares pre Phase I then there was less than 33 million shares outstanding. There has been close to $500 million spent on the development of RVX208 between then and now and quite a few shares have been issued in order to fund that development. There is roughly 6X's the number of shares outstanding today versus then and there is still a ways to go before apabetalone potentially hits the market. More money will be required to get us there unless we are taken out sooner. This is very normal for a company that only spends money. Most Biotects only spend money to developed a drug and then the lucky ones sell that drug. Many more development stage Biotects don't make it to this point. Coo dose to management and the scientists for getting us to this point. Getting us over the next hump will put us much closer to putting money in our pockets. If that means a share consolidation of some sort is required so be it.

dyodd

tada